ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer.
Publication/Presentation Date
3-13-2024
Abstract
Pancreatic ductal adenocarcinoma (PDAC) manifests diverse molecular subtypes, including the classical/progenitor and basal-like/squamous subtypes, with the latter known for its aggressiveness. We employed integrative transcriptome and metabolome analyses to identify potential genes contributing to the molecular subtype differentiation and its metabolic features. Transcriptome analysis in PDAC patient cohorts revealed downregulation of adrenoceptor alpha 2A (ADRA2A) in the basal-like/squamous subtype, suggesting its potential role as a candidate suppressor of this subtype. Reduced ADRA2A expression was significantly associated with a high frequency of lymph node metastasis, higher pathological grade, advanced disease stage, and decreased survival among PDAC patients.
ISSN
2692-8205
Published In/Presented At
Moreno, P., Ohara, Y., Craig, A. J., Liu, H., Yang, S., Zhang, L., Panigrahi, G., Dorsey, T. H., Cawley, H., Azizian, A., Gaedcke, J., Ghadimi, M., Hanna, N., & Perwez Hussain, S. (2024). ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. bioRxiv : the preprint server for biology, 2024.03.12.584316. https://doi.org/10.1101/2024.03.12.584316
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
38903083
Department(s)
Administration and Leadership
Document Type
Article